Magnetic magnetite nanoparticles (MNP) are heralded as model vehicles for nanomedicine, particularly cancer therapeutics. However, there are many methods of synthesizing different sized and coated MNP, which may affect their performance as nanomedicines. Magnetosomes are naturally occurring, lipid-coated MNP that exhibit exceptional hyperthermic heating, but their properties, cancer cell uptake and toxicity have yet to be compared to other MNP. Magnetosomes can be mimicked by coating MNP in either amphiphilic oleic acid or silica. In this study, magnetosomes are directly compared to control MNP, biomimetic oleic acid and silica coated MNP of varying sizes. MNP are characterized and compared with respect to size, magnetism, and surface properties. Small (8 ± 1.6 nm) and larger (32 ± 9.9 nm) MNP are produced by two different methods and coated with either silica or oleic acid, increasing the size and the size dispersity of the MNP. The coated larger MNP are comparable in size (49 ± 12.5 nm and 61 ± 18.2 nm) to magnetosomes (46 ± 11.8 nm) making good magnetosome mimics. All MNP are assessed and compared for cancer cell uptake in MDA-MB-231 cells and importantly, all are readily taken up with minimal toxic effect. Silica coated MNP show the most uptake with greater than 60% cell uptake at the highest concentration, and magnetosomes showing the least with less than 40% at the highest concentration, while size does not have a significant effect on uptake. Finally, surface functionalization is demonstrated for magnetosomes and silica coated MNP using biotinylation and EDC-NHS, respectively, to conjugate fluorescent probes. The modified particles are visualized in MDA-MB-231 cells and demonstrate how both naturally biosynthesized magnetosomes and biomimetic silica coated MNP can be functionalized and readily up taken by cancer cells for realization as nanomedical vehicles.
Background: Oncolytic viruses (OV) are encouraging new immunotherapies for cancer. OVs, replicate in cancer cells inducing immunogenic cell death (ICD) and activating antitumor immunity. To date, clinical use has focused on intratumoral delivery due to concerns over inadequate tumor targeting following systemic administration. We hypothesize that magnetizing OVs and magnetic guidance strategies will improve systemic delivery by protecting the viruses from inactivating immune mechanisms and non-specific adsorption. Methods: To investigate this, we synthesized and characterized complexes of magnetized oncolytic herpes simplex virus (HSV1716) co-assembled with biocompatible magnetic nanoparticles (MAG) derived from magnetotactic bacteria (AMB-1) to give MAG-HSV1716 complexes. Characterization of the physical, chemical and oncolytic potential of our MAG-HSV1716 was performed. The safety and efficacy of our nanomedicine in combination with magnetic guidance strategies were also assessed in vivo. Results: Stable MAG-HSV1716 complexes of ~160nm diameter successfully infected human and murine breast cancer cells in a dose-dependent manner, and induced tumor oncolysis. Following MAG-HSV1716 infection a significant increase in viral replication (ICP0, gB, ICP8), ICD (HMGB1, CALR, ATP) and apoptotic (CASP 3, CASP8, FASL) signals were detected. Intravenous delivery of MAG-HSV1716 resulted in reduced tumour burden in the presence of magnetic guidance (MAG-HSV1716 448.3mm³ vs. HSV1716 670.6mm³; p ≤ 0.05, n=6-9 mice/group) and an increase in tumor-infiltrating T-cells, NK cells and neutrophils. Furthermore, MAG-HSV1716 were protective in the presence of neutralizing Abs both in vitro and in vivo. Conclusion: This study indicates that magnetizing HSV1716 results in viral protection from neutralizing antibodies and in combination with magnetic guidance reduces tumor burden and induces anti-tumor immunity. Citation Format: Haider AL-Janabi, Joe Conner, Faith Howard, Stuart Hunt, Zainab Taher, Sarah Staniland, Munitta Muthana. Breast cancer immunotherapy using magnetized HSV1716 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr LB-188.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.